Cabaletta Bio
CABA
86 hedge funds and large institutions have $111M invested in Cabaletta Bio in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 32 closing their positions.
1,087% more call options, than puts
Call options by funds: $1.8M | Put options by funds: $152K
120% more capital invested
Capital invested by funds: $50.3M → $111M (+$60.3M)
69.13% more ownership
Funds ownership: 74.27% → 143.4% (+69%)
7% less funds holding
Funds holding: 92 → 86 (-6)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
19% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$10.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.8M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$7.49M |
| 5 |
Jennison Associates
New York
|
+$5.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.87M |
| 2 |
CF
Cantor Fitzgerald
New York
|
-$1.48M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$1.18M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.12M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.04M |
CABA Hedge Fund Activity: Q2 2025 in Review
86 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cabaletta Bio (CABA) for Q2 2025, worth a combined $111M — up 120% from $50.3M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of CABA and 26 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 23 added.
The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $10.8M. The largest seller was BlackRock, cutting an estimated $3.87M.
- 86 institutional investors held Cabaletta Bio (CABA) as of Q2 2025, down from 92 in Q1 2025.
- Funds reported $111M of Cabaletta Bio stock for Q2 2025, up 120% quarter-over-quarter.
- 26 funds opened new Cabaletta Bio positions in Q2 2025 and 32 closed out, a net change of -6 holders.
- The largest Cabaletta Bio buyer in Q2 2025 was Bain Capital Life Sciences Investors, an estimated $10.8M added.
- The largest Cabaletta Bio seller in Q2 2025 was BlackRock, an estimated $3.87M sold.
Based on aggregated 13F filings for Q2 2025.